持股变动声明
Lantern Pharma(LTRN)03-01 11:05
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029534 Size: 41 KB 网页链接
简介：Lantern Pharma Inc.成立于2013年11月7日。该公司是一家临床阶段生物技术公司，致力于利用人工智能（“A.I.”），机器学习和基因组数据来简化药物开发流程并使将要治疗的患者能从其靶向肿瘤治疗中受益。
| 今开：5.55 | 昨收：5.46 |
| 最高：6.04 | 最低：5.46 |
| 涨停价： | 跌停价： |
| 总市值：60366241 |
Lantern Pharma(LTRN)03-01 11:05
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029534 Size: 41 KB 网页链接
Lantern Pharma(LTRN)03-02 05:15
$Lantern Pharma(LTRN)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-029971 Act: 34 Size: 319 KB 网页链接
Lantern Pharma(LTRN)03-19 04:15
$Lantern Pharma(LTRN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001493152-24-010302 Act: 34 Size: 9 MB 网页链接
Lantern Pharma(LTRN)03-01 11:05
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029533 Size: 30 KB 网页链接
Lantern Pharma(LTRN)03-19 04:15
$Lantern Pharma(LTRN)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001493152-24-010303 Act: 34 Size: 8 MB 网页链接
Lantern Pharma(LTRN)02-29 10:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028948 Act: 33 Size: 5 KB 网页链接
Lantern Pharma(LTRN)02-29 10:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028949 Act: 33 Size: 5 KB 网页链接
Lantern Pharma(LTRN)02-29 10:45
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028950 Act: 33 Size: 5 KB 网页链接
Lantern Pharma(LTRN)02-15 05:15
$Lantern Pharma(LTRN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001493152-24-006658 Act: 34 Size: 48 KB 网页链接
牛股小红书2022-01-13 10:55
$Lantern Pharma(LTRN)$ 宣布扩大与美国国立卫生研究院（National Institutes of Health）国家癌症研究所（NCI）的合作协议。
公司表示，这项合作的扩大是在确定了几个基因特征之后进行的，这些基因特征预测了患者肿瘤对Lantern的候选药物LP-184和LP-284的潜在反应。
LP-184作为一种新的...查看全文
bdkfbfkockd994642021-08-26 20:52
$Lantern Pharma(LTRN)$ 这个公司一个人都没有关注吗。。。查看全文
$Lantern Pharma(LTRN)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001493152-24-010303 Act: 34 Size: 8 MB 网页链接
$Lantern Pharma(LTRN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001493152-24-010302 Act: 34 Size: 9 MB 网页链接
$Lantern Pharma(LTRN)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-029971 Act: 34 Size: 319 KB 网页链接
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029534 Size: 41 KB 网页链接
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029533 Size: 30 KB 网页链接
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028950 Act: 33 Size: 5 KB 网页链接
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028948 Act: 33 Size: 5 KB 网页链接
$Lantern Pharma(LTRN)$ 144 Report of proposed sale of securities Accession Number: 0001104659-24-028949 Act: 33 Size: 5 KB 网页链接
$Lantern Pharma(LTRN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001493152-24-006658 Act: 34 Size: 48 KB 网页链接
$Lantern Pharma(LTRN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-005238 Size: 31 KB 网页链接